Gene Therapy for Head and Neck Cancer Using Vaccinia Virus Expressing IL-2 in a Murine Model, with Evidence of Immune Suppression
Open Access
- 1 December 2001
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 4 (6) , 551-558
- https://doi.org/10.1006/mthe.2001.0493
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Tumor-Induced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by Cytokine-Secreting Tumor VaccineHuman Gene Therapy, 2000
- The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck CancerMolecular Endocrinology, 1997
- Interactions between Autologous CD4+and CD8+T Lymphocytes and Human Squamous Cell Carcinoma of the Head and NeckCellular Immunology, 1997
- Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancerInternational Journal of Cancer, 1996
- Head and Neck CancerNew England Journal of Medicine, 1993
- Interleukin‐2 injected around tumor‐draining lymph nodes in head and neck cancerHead & Neck, 1991
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Recombinant vaccinia virus expressing epstein‐barr virus glycoprotein gp340 protects cottontop tamarins against EB virus‐induced malignant lymphomasJournal of Medical Virology, 1988
- Distribution and modulation of the cellular receptor for transforming growth factor-beta.The Journal of cell biology, 1987